FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Praxis für Hämatologie und Onkologie Koblenz
Industry / private company
Location:
Koblenz, Germany (DE)
ISNI
: -
Publications
(6)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (2022)
Burchert A, Saussele S, Michel C, Metzelder SK, Hochhaus A, Gattermann N, Crysandt M, et al.
Conference contribution
Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288, (Annals of Oncology (2019) 30(1279-1288) (S0923753419312785)) (2022)
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al.
Journal article, Erratum
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial (2022)
Gerber B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, et al.
Journal article
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC (2020)
Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, et al.
Journal article
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study (2019)
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al.
Journal article
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial (2019)
Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J, et al.
Journal article